| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | Eukaryotic cells with artificial endosymbionts for multimodal detection | US15079453 | 2016-03-24 | US09446154B2 | 2016-09-20 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 102 | Method and Device for Combined Detection of Viral and Bacterial Infections | US15164137 | 2016-05-25 | US20160266119A1 | 2016-09-15 | Robert P. Sambursky; Robert W. VanDine; Uma Mahesh Babu; Peter Condon |
| A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample. | ||||||
| 103 | DETECTION ASSAYS AND METHODS | US15055217 | 2016-02-26 | US20160252502A1 | 2016-09-01 | Abdennour Abbas |
| This disclosure describes assay methods and kits for detecting a target. The methods and kits can be used to detect a target that is present in a sample at low concentration because the methods and kits amplify the signal indicating the presence of target in the sample. Generally, the methods and kits involve nanoparticle aggregation as a detectable signal that is enhanced by a trigger released from a vesicular compartment when the target is bound to a capture agent. | ||||||
| 104 | ANTIBODIES DIRECTED AGAINST INFLUENZA | US15083515 | 2016-03-29 | US20160200800A1 | 2016-07-14 | Rafi Ahmed; Jens Wrammert; Patrick C. Wilson |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 105 | Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection | US15079453 | 2016-03-24 | US20160199518A1 | 2016-07-14 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 106 | Eukaryotic cells with artificial endosymbionts for multimodal detection | US14689987 | 2015-04-17 | US09315780B2 | 2016-04-19 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 107 | Method and Device for Combined Detection of Viral and Bacterial Infections | US14956956 | 2015-12-02 | US20160084832A1 | 2016-03-24 | Robert P. Sambursky; Robert W. VanDine; Uma Mahesh Babu; Peter Condon |
| A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample. | ||||||
| 108 | Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes | US12922850 | 2009-03-16 | US09200063B2 | 2015-12-01 | Roberto Burioni; Massimo Clementi |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. | ||||||
| 109 | RISK STRATIFICATION IN INFLUENZA | US14410367 | 2013-07-10 | US20150322538A1 | 2015-11-12 | Anthony McLean; Benjamin Tang; Grant Peter Parnell; Maryam Shojaei |
| The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | ||||||
| 110 | Eukaryotic Cells with Artificial Endosymbionts for Multimodal Detection | US14332373 | 2014-07-15 | US20150010937A1 | 2015-01-08 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 111 | MICROSTRUCTURED CHIP FOR SURFACE PLASMON RESONANCE ANALYSIS, ANALYSIS DEVICE CONTAINING SAID MICROSTRUCTURED CHIP AND USE OF SAID DEVICE | US14354253 | 2012-10-25 | US20140371093A1 | 2014-12-18 | Thibaut Mercey |
| A microstructured chip (3; 33; 43; 53; 63) for surface plasmon resonance (SPR) analysis, taking the form of a solid formed by: a base (5; 77); an upper surface (4; 44), at least part of which is covered with a metal layer (2; 22; 42; 52; 62); and at least one side surface (55; 66). The chip is characterized in that the aforementioned upper surface is provided with micrometric zones intended to receive species to be analysed and selected from among n protrusions and m cavities, and in that when n+m≧2 the zones are separated from one another by planar surfaces, with n varying between 1 and j, m varying between 0 and i, and j and i being integers. | ||||||
| 112 | Quantitative multiplex detection of pathogen biomarkers | US12924929 | 2010-10-08 | US08859268B2 | 2014-10-14 | Harshini Mukundan; Hongzhi Xie; Basil I. Swanson; Jennifer Martinez; Wynne K. Grace |
| The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel. | ||||||
| 113 | Anthrax carbohydrates, synthesis and uses thereof | US12317693 | 2008-12-24 | US08420607B2 | 2013-04-16 | Russell W. Carlson; Geert-Jan Boons; Conrad Quinn; Mahalakshmi Vasan; Margreet A. Wolfert; Therese Buskas; Biswa Choudhury; Elmar Kannenberg; Christine Leoff; Alok Mehta; Elke Saile; Jana Rauvolfova; Patricia Wilkins |
| The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies. | ||||||
| 114 | SDRE protein from Staphylococcus aureus and diagnostic kits including same | US12546322 | 2009-08-24 | US07855272B2 | 2010-12-21 | Joseph M. Patti; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A. O. Hook; Samuel E. Perkins |
| An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. | ||||||
| 115 | Anthrax carbohydrates, synthesis and uses thereof | US12317693 | 2008-12-24 | US20100233174A9 | 2010-09-16 | Russell W. Carlson; Geert-Jan Boons; Therese Buskas; Biswa Choudhury; Elmar Kannenberg; Christine Leoff; Alok Mehta; Elke Saile; Jana Rauvolfova; Conrad Quinn; Patricia Wilkins; Mahalakshmi Vasan; Margreet A. Wolfert |
| The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies. | ||||||
| 116 | Toxoplasma gondii oocyst protein | US12436596 | 2009-05-06 | US07741063B2 | 2010-06-22 | Dolores Hill; Dante S Zarlenga; Cathleen Coss; Jitender P Dubey |
| Recombinant proteins have been developed for the detection of Toxoplasma gondii oocyst proteins for example in biological fluids. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of cells and the production of the proteins. | ||||||
| 117 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS | US12546322 | 2009-08-24 | US20100113349A1 | 2010-05-06 | Joseph M. PATTI; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A.O. Hook; Samuel E. Perkins |
| An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. | ||||||
| 118 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS | US12546268 | 2009-08-24 | US20100008943A1 | 2010-01-14 | Joseph M. Patti; Timothy J. Foster; Elizabet Joseffson; Deidre Ni Eidhin; Magnus A. O. Hook; Samuel E. Perkins |
| An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. | ||||||
| 119 | Toxoplasma gondii Oocyst Protein | US12436508 | 2009-05-06 | US20090215087A1 | 2009-08-27 | Dolores E. Hill; Dante S. Zarlenga; Cathleen Coss; Jitender P. Dubey |
| Recombinant proteins have been developed for the detection of Toxoplasma gondii oocyst proteins for example in biological fluids. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of cells and the production of the proteins. | ||||||
| 120 | Extracellular matrix-binding proteins from Staphylococcus aureus | US10744672 | 2003-12-24 | US07381793B2 | 2008-06-03 | Joseph M. Patti; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A. O. Hook; Samuel E. Perkins |
| Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD. | ||||||
QQ群二维码
意见反馈
意见反馈